Organon (OGN) Depreciation & Amortization (CF) (2020 - 2026)
Organon (OGN) recorded quarterly Depreciation & Amortization (CF) of $39.0 million in Q1 2026, down 15.22% quarter-over-quarter from $46.0 million in Q4 2025, and up 14.71% on a YoY basis from $34.0 million in Q1 2025.
Organon (OGN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Organon's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $39.0 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 14.71% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $161.0 million (up 20.15% YoY), while the FY2025 annual figure was $156.0 million, up 18.18% from the prior year.
- Depreciation & Amortization (CF) was $39.0 million for Q1 2026 at Organon, down from $46.0 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $46.0 million in Q4 2025 to a low of $22.0 million in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $31.9 million across 5 years, with a median of $32.0 million in 2023.
- Biggest YoY gain for Depreciation & Amortization (CF) was 38.89% in 2022; the steepest drop was 14.29% in 2022.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $24.0 million in 2022, then surged by 33.33% to $32.0 million in 2023, then climbed by 6.25% to $34.0 million in 2024, then jumped by 35.29% to $46.0 million in 2025, then dropped by 15.22% to $39.0 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $39.0 million (Q1 2026), $46.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 509.00 Mn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 594.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 39.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.00 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Dec 31, 2025 | 46.00 Mn |
| Dec 31, 2025 | 46.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 36.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | 32.00 Mn |
| Dec 31, 2023 | 32.00 Mn |